DC4 Stock Chart & Stats
€78.20
€0.00(0.00%)
At close: 4:00 PM EDT
€78.20
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€47.00 - €79.60
Previous CloseN/A
Volume0.00
Average Volume (3M)187.00
Market Cap
€27.48B
Enterprise Value€25.72K
Total Cash (Recent Filing)€1.95B
Total Debt (Recent Filing)€1.40B
Price to Earnings (P/E)32.1
Beta0.92
Next Earnings
Oct 22, 2026EPS Estimate
0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.59
Shares Outstanding377,360,780
10 Day Avg. Volume32
30 Day Avg. Volume187
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)9.43
Price to Sales (P/S)5.56
P/FCF Ratio24.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€80.10Price Target Upside2.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)2.29
Revenue Forecast (FY)€4.49B
Bulls Say, Bears Say
Bulls Say
Recurring CGM Revenue ModelThe recurring replacement cycle for disposable sensors supports predictable repeat revenue and improves customer retention economics. As the installed base expands, ongoing sensor demand can provide durable revenue visibility while complementary transmitters, receivers, and software integrations deepen the customer relationship.
Strong Margins And Cash GenerationHigh and improving margins indicate meaningful operating leverage as Dexcom scales, while substantial free cash flow demonstrates the business can convert growth into internal funding. This combination supports investment in capacity and innovation, strengthens resilience, and gives management flexibility in capital allocation.
Clinical Evidence And Reimbursement ExpansionBroader reimbursement expands the addressable CGM population and reduces access barriers, supporting adoption beyond traditional insulin users. Clinical evidence showing better glucose outcomes can reinforce payer support and physician confidence, creating a durable foundation for utilization and long-term customer growth.
Bears Say
Revenue Growth Has DeceleratedThe sharp slowdown from prior growth rates raises questions about how quickly Dexcom can continue expanding its user base and revenue scale. If sustained, slower growth could limit future operating leverage and make it harder to maintain the pace of margin improvement achieved in recent years.
Medicare Coverage Timing Remains UncertainMedicare coverage could materially expand access, but uncertain timing and potential conditions make that opportunity difficult to rely on over the next several quarters. Delays or restrictive terms could postpone adoption among eligible patients and leave an important growth catalyst less predictable.
Ireland Expansion May Pressure MarginsThe capacity investment is intended to support future production, but hiring, training, and depreciation create a period of execution risk and cost absorption. These expenses may temporarily dilute margin expansion and require successful ramp-up before the added infrastructure contributes efficiently to profitability.
Dexcom News
DC4 FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was €47.00 and its highest was €79.60 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is €27.48B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Oct 22, 2026 which is in 40 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Jul 30, 2026. The company reported €0.601 earnings per share for the quarter, beating the consensus estimate of €0.525 by €0.076.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.58.
How many shares outstanding does Dexcom have?
Dexcom has 377,360,780 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of €0.601 in its last earnings report, beating expectations of €0.525. Following the earnings report the stock price went up 12.226%.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in DE:DC4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dexcom Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€80.10 (2.43% Upside)
€80.10 (2.43% Upside)
Blogger Sentiment
Bullish
DE:DC4 Sentiment 73%
Sector Average 62%
Sector Average 62%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Dexcom
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
DC4 Company Deck
DC4 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive operational and financial message: double-digit revenue growth, substantial margin expansion (400 bps YoY), strong cash generation, successful product rollouts and encouraging clinical data (CONNECT) that is driving payer coverage momentum. Near-term headwinds include FX impact, Ireland manufacturing ramp costs, tougher international comps in the back half, and remaining uncertainties around Medicare coverage terms and timing. Overall, achievements and momentum on growth, margins, cash flow, product adoption and clinical evidence substantially outweigh the manageable near-term challenges.View all DE:DC4 earnings summariesDC4 Revenue Breakdown
71.53% U.S.
28.47% International
DC4 Stock 12 Month Forecast
Average Price Target
€80.10
▲(2.43% Upside)
Technical Analysis
Abbott Laboratories
―
Insulet
―
Medtronic
―
Tandem Diabetes Care
―
Senseonics Holdings
―